High energy and higher hopes: Cannabis Expo 2025 lights up Sandton
Another year, another Cannabis Expo – this time with even more flair, innovation and excitement. This year's Cannabis Expo kicked off with an electrifying buzz at the Sandton Convention Centre, drawing overwhelming enthusiasm from attendees, exhibitors and industry leaders alike.
From the moment the doors opened, the atmosphere was charged with palpable energy as a record-breaking crowd poured in. With more than 100 exhibitors from SA and beyond, the expo offered a vibrant showcase of the cannabis industry's full spectrum – spanning cultivation, extraction, medicinal advancements, lifestyle products and retail innovations.
This year's event promises to be the most dynamic yet, reflecting the growing momentum and mainstream acceptance of the cannabis economy.
The expo runs until Sunday, providing a platform not just for business and education, but for igniting conversations and sparking new collaborations in the evolving cannabis space.
Beyond the buzzing exhibition floor, the atmosphere came alive with the Freedom Festival, which delivered an unforgettable cultural experience. A stellar lineup of local DJs kept the energy high, transforming the event into a vibrant celebration of music, community and cannabis culture.
Crowds flocked to the fan-favourite Speed Rolling competition, adding a fun and competitive edge to the day's festivities.
With a packed weekend still ahead, organisers anticipate record-breaking attendance. The expo remains open daily from 10am to 6pm through Sunday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
an hour ago
- New York Times
Trump Targets Key Lifeline for Africa: Money Sent Home by Immigrants
The Trump administration's 'One Big, Beautiful Bill' could make the United States the most expensive of the Group of 7 countries from which to send money, dealing another blow to poor nations already reeling from recent aid cuts. As part of the bill, the U.S. government would take a cut of all remittances sent to foreign nations, a move that would hit millions of families worldwide who rely on money sent from loved ones working in America. Latin American countries would lose several billion dollars if the bill passes the Senate. But for African nations, where poverty levels are far higher, remittances are even more of a lifeline. The bill's passage would be the latest sign of a U.S. retreat from Africa, coming on the heels of the gutting of the Agency for International Development and the introduction of steep tariffs after decades of preferential trade agreements on the continent. People receiving remittances from abroad are, like aid recipients, often the very poorest. In Africa, Nigerians would pay the most under the bill in absolute terms, losing around $215 million. Gambia and Liberia would lose the most as a percentage of gross national income; for both countries, around a quarter now comes from remittances. Senegal, which the World Bank ranked the country most dependent on remittances, would also suffer. Want all of The Times? Subscribe.
Forbes
3 hours ago
- Forbes
EVs Are Rewiring Risk For Manufacturers
The internal combustion engine (ICE) has been steadily improving for more than 100 years, giving us cars that are almost unrecognisable from those early, groundbreaking days of the Ford Model T. This, in turn, has made driving a faster, safer, more fuel-efficient, and more enjoyable experience for everyone. Now electric vehicles (EVs) mark a fundamental shift. One that not only paves the way to innovative changes in how passenger vehicles are designed, built, and maintained, but that will also kickstart a whole new era of risk for manufacturers. Driving this transformation are three key factors, the first of which is consumer dynamics. To date, EV adoption has actually been slower than many projected with only a quarter of car buyers seriously considering going fully electric due to concerns around cost, range and charging time. This has seen the manufacturing industry double down on addressing these concerns with new models that travel further and charge faster. The second factor is battery innovation. Right now, lithium-ion is found in 90% of US EVs, but their performance and safety features don't completely meet all customer requirements. Interest in alternative designs is therefore accelerating too – from iron- and sulphur-based lithium variants to sodium-ion and hydrogen cells. All have their own advantages and disadvantages, leading manufacturers to invest in understanding how they perform in the full life cycle of a user experience. The third and final driver of change is the supply chain itself. EVs use up to three times more chips than ICE vehicles and therefore rely heavily on materials sourced and processed overseas. China alone accounts for 70% of global battery production. Add in geopolitical volatility, tariff controversies, ongoing labor shortages, and localized incidents like the collapse of the Francis Scott Key Bridge, and it's clear: EV supply chains are more stretched and unpredictable than ever – requiring flexible and proactive risk mitigation frameworks to match. There are new, less familiar threats for manufacturers to counter too. While ICE and hybrid vehicles actually catch fire more frequently, EV fires tend to burn hotter and longer – with several high-profile cases making the news and rocking consumer trust. Responding to this risk requires specialized equipment and training for staff, along with a deeper knowledge of chemistry, housing, and fire suppression. Then there's cyber. EVs are, by nature, software-defined machines that are deeply integrated with networks and cloud platforms. From code-level bugs to coordinated hacks, this opens up new areas of potential vulnerability, all capable of causing costly reputational damage and liability claims. Even product recalls are changing. In contrast to ICE vehicle breakdowns, EV issues can often be fixed with over-the-air updates and patches. Yet while the National Highway Traffic Safety Administration (NHTSA) still classifies these events as recalls, the cost and customer experience are entirely different. This, in turn, forces insurers and manufacturers to re-examine the way they calculate risk along with how they structure mitigation strategies going forward. So how should the manufacturing industry respond? First and foremost, by empowering risk managers to lead in this evolving environment and become a central part of a broader, stronger, more connected ecosystem within their own companies. One that connects stakeholders across R&D, supply chain, operations, IT, and even government relations to create a comprehensive framework for analysing and responding to risk. The way manufacturers deploy data must evolve too. Unlike with ICE vehicles, firms don't have decades of EV insights to fall back on in their decision-making and planning. So instead, they should lean into forward-looking indicators, using machinery data on the shop floor to identify quality risks and limit the likelihood of product liability and recall. Leveraging smarter building data in areas like fire protection and structural soundness will also be vital, as will utilizing supply chain visibility information and scoring models for business tax. Encouragingly, much of this data is already available today; it now just needs to be viewed with a risk lens. Rather than simply present data at renewal time, manufacturers and brokers should therefore engage in an ongoing dialogue with carriers about emerging threats, evolving mitigations, and the specific steps they are taking to reduce exposure. This will help shape limits and premiums that fit the realities of their operating landscape. In fact, this ability to focus on the future is, perhaps, the most important shift of all. As EVs become an ever more frequent sight on our roads and in our factories, the passenger vehicle market will be defined by both new methods of manufacturing and new approaches to risk. The firms that lead this new era will be those with their eyes on the road ahead, not in the rear view mirror.
Associated Press
4 hours ago
- Associated Press
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
WOBURN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the inclusion of the patent for its propylene glycol-free formulation of Ameluz® nanoemulsion gel in the US Food and Drug Administration's (FDA's) publication 'Approved Drug Products with Therapeutic Equivalence Evaluations' (commonly known as the Orange Book). The Orange Book is a key reference for healthcare providers, pharmacists, and payers and is the definitive source for identifying FDA-approved drug products. Inclusion of a drug in the Orange Book confirms that the FDA recognizes that the drug meets their rigorous standards for safety, efficacy, and quality. In addition, patents listed confer intellectual property protections which may include the drug's composition, formulation, or specific uses. Listing of the patent for the propylene glycol-free formulation of Ameluz® prevents generic competition as long as the patent is valid, which currently is December 2043. The revised formulation, which eliminates propylene glycol—a well-known allergen for some patients1—demonstrates Biofrontera's continued commitment to innovation and patient-centric development. It offers a significant improvement for individuals who are sensitive to this excipient without compromising the treatment's effectiveness. The patent for the revised formulation of Ameluz® was issued on April 22, 2025, and lasts until December 8, 2043. The formulation itself was accepted by the FDA and has been in use since 2024. 'We are proud to announce the inclusion of the patent for our propylene glycol-free formula in the Orange Book,' said Dr Hermann Luebbert, CEO and Chairman of Biofrontera Inc. 'This recognition validates the differentiated profile of our propylene glycol-free formulation, offering physicians and patients a formulation that reduces the potential for allergic reactions while maintaining the efficacy of Ameluz® RhodoLED PDT.' References: About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit and follow Biofrontera on LinkedIn and Twitter. Forward-Looking Statements Certain statements in this press release may constitute 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera's commercial opportunities and the commercial success of its licensed products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of any extraordinary external events; any changes in the Company's relationship with its licensors; the ability of the Company's licensors to fulfill their obligations to the Company in a timely manner; the Company's ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company's ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company's licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED and/or RhodoLED XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz in combination with BF- RhodoLED and/or RhodoLED XL is consistent with the Company's expectations; the Company's ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing; and other factors that may be disclosed in the Company's filings with the Securities and Exchange Commission (the 'SEC'), which can be obtained on the SEC's website at Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. Contact: Investor Relations Andrew Barwicki 1-516-662-9461 [email protected]
